Key Drivers
- Strong Liquidity
- Weak Quarter
- Cash Conversion
AIAI Summary
TCMD should now be viewed as a proof-of-execution story rather than a clean medtech compounder: 23% revenue growth and 76.5% gross margins show demand is real, but negative operating income/free cash flow mean investors need to see sustained conversion from growth into durable earnings before the stock can de-risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Weak Quarter
- •Cash Conversion
TCMD has a strong, low-leverage balance sheet and solid full-year cash profitability, but the latest quarter showed a sharp earnings and free-cash-flow deterioration that tempers the outlook.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support holding
- •Rebound failed
Over the last month, TCMD has weakened into a mixed-to-bearish setup, with buyers defending the low-$22s but repeated failures near $23.90–$24.05 and lower highs suggesting another test of $22.50 could be next.
Quick rebound from $22.51 to $26.01 failed, followed by lower highs and lower closes
Sentiment & News
Key News Insights:
- •Revenue Surge
- •Margin Expansion
- •EPS Miss
TCMD delivered strong Q1 revenue and margin gains with positive EBITDA, but a small EPS miss and recent share weakness temper the otherwise improving operational outlook.
The report is modestly positive for TCMD's fundamentals, but near-term stock performance may stay sensitive until earnings consistency improves
Similar Companies in Healthcare
Other companies in the same sector with AI ratings